
Global Semi-Solid Dosage Form Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Semi-Solid Dosage Form market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Semi-Solid Dosage Form include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Semi-Solid Dosage Form, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Semi-Solid Dosage Form.
The Semi-Solid Dosage Form market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Semi-Solid Dosage Form market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Semi-Solid Dosage Form Segment by Company
Aclaris Therapeutics, Inc.
Akorn Inc. (US)
Allergan plc
Almirall, S.A
Bausch Health Companies
Biofrontera, Inc.
Cipla Ltd
Crescita Therapeutics Inc.
Crown Laboratories Inc.
Encore Dermatology, Inc.
Glenmark Pharmaceuticals
Hisamitsu Pharmaceutical
Ingenus Pharmaceuticals
LEO Pharma
Mylan N.V.
Novartis AG
Perrigo Pharma
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Bayer AG
GlaxoSmithKline plc
Merck & Co
Johnson & Johnson
Nestlé SA
Sun Pharmaceuticals
Semi-Solid Dosage Form Segment by Type
Ointments
Gels
Others
Semi-Solid Dosage Form Segment by Application
Nasal Cavity
Skin
Vaginal Cavity
Rectal Cavity
Others
Semi-Solid Dosage Form Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
According to APO Research, The global Semi-Solid Dosage Form market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Semi-Solid Dosage Form is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Semi-Solid Dosage Form include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Semi-Solid Dosage Form, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Semi-Solid Dosage Form.
The Semi-Solid Dosage Form market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Semi-Solid Dosage Form market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Semi-Solid Dosage Form Segment by Company
Aclaris Therapeutics, Inc.
Akorn Inc. (US)
Allergan plc
Almirall, S.A
Bausch Health Companies
Biofrontera, Inc.
Cipla Ltd
Crescita Therapeutics Inc.
Crown Laboratories Inc.
Encore Dermatology, Inc.
Glenmark Pharmaceuticals
Hisamitsu Pharmaceutical
Ingenus Pharmaceuticals
LEO Pharma
Mylan N.V.
Novartis AG
Perrigo Pharma
Taro Pharmaceutical Industries Ltd.
Teligent Pharma
Bayer AG
GlaxoSmithKline plc
Merck & Co
Johnson & Johnson
Nestlé SA
Sun Pharmaceuticals
Semi-Solid Dosage Form Segment by Type
Ointments
Gels
Others
Semi-Solid Dosage Form Segment by Application
Nasal Cavity
Skin
Vaginal Cavity
Rectal Cavity
Others
Semi-Solid Dosage Form Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Table of Contents
123 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Semi-Solid Dosage Form Market Size Estimates and Forecasts (2020-2031)
- 1.2.2 Global Semi-Solid Dosage Form Sales Estimates and Forecasts (2020-2031)
- 1.3 Semi-Solid Dosage Form Market by Type
- 1.3.1 Ointments
- 1.3.2 Gels
- 1.3.3 Others
- 1.4 Global Semi-Solid Dosage Form Market Size by Type
- 1.4.1 Global Semi-Solid Dosage Form Market Size Overview by Type (2020-2031)
- 1.4.2 Global Semi-Solid Dosage Form Historic Market Size Review by Type (2020-2025)
- 1.4.3 Global Semi-Solid Dosage Form Forecasted Market Size by Type (2026-2031)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Semi-Solid Dosage Form Sales Breakdown by Type (2020-2025)
- 1.5.2 Europe Semi-Solid Dosage Form Sales Breakdown by Type (2020-2025)
- 1.5.3 Asia-Pacific Semi-Solid Dosage Form Sales Breakdown by Type (2020-2025)
- 1.5.4 South America Semi-Solid Dosage Form Sales Breakdown by Type (2020-2025)
- 1.5.5 Middle East and Africa Semi-Solid Dosage Form Sales Breakdown by Type (2020-2025)
- 2 Global Market Dynamics
- 2.1 Semi-Solid Dosage Form Industry Trends
- 2.2 Semi-Solid Dosage Form Industry Drivers
- 2.3 Semi-Solid Dosage Form Industry Opportunities and Challenges
- 2.4 Semi-Solid Dosage Form Industry Restraints
- 3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Semi-Solid Dosage Form Revenue (2020-2025)
- 3.2 Global Top Players by Semi-Solid Dosage Form Sales (2020-2025)
- 3.3 Global Top Players by Semi-Solid Dosage Form Price (2020-2025)
- 3.4 Global Semi-Solid Dosage Form Industry Company Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Semi-Solid Dosage Form Major Company Production Sites & Headquarters
- 3.6 Global Semi-Solid Dosage Form Company, Product Type & Application
- 3.7 Global Semi-Solid Dosage Form Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Semi-Solid Dosage Form Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Semi-Solid Dosage Form Players Market Share by Revenue in 2024
- 3.8.3 2023 Semi-Solid Dosage Form Tier 1, Tier 2, and Tier 3
- 4 Semi-Solid Dosage Form Regional Status and Outlook
- 4.1 Global Semi-Solid Dosage Form Market Size and CAGR by Region: 2020 VS 2024 VS 2031
- 4.2 Global Semi-Solid Dosage Form Historic Market Size by Region
- 4.2.1 Global Semi-Solid Dosage Form Sales in Volume by Region (2020-2025)
- 4.2.2 Global Semi-Solid Dosage Form Sales in Value by Region (2020-2025)
- 4.2.3 Global Semi-Solid Dosage Form Sales (Volume & Value), Price and Gross Margin (2020-2025)
- 4.3 Global Semi-Solid Dosage Form Forecasted Market Size by Region
- 4.3.1 Global Semi-Solid Dosage Form Sales in Volume by Region (2026-2031)
- 4.3.2 Global Semi-Solid Dosage Form Sales in Value by Region (2026-2031)
- 4.3.3 Global Semi-Solid Dosage Form Sales (Volume & Value), Price and Gross Margin (2026-2031)
- 5 Semi-Solid Dosage Form by Application
- 5.1 Semi-Solid Dosage Form Market by Application
- 5.1.1 Nasal Cavity
- 5.1.2 Skin
- 5.1.3 Vaginal Cavity
- 5.1.4 Rectal Cavity
- 5.1.5 Others
- 5.2 Global Semi-Solid Dosage Form Market Size by Application
- 5.2.1 Global Semi-Solid Dosage Form Market Size Overview by Application (2020-2031)
- 5.2.2 Global Semi-Solid Dosage Form Historic Market Size Review by Application (2020-2025)
- 5.2.3 Global Semi-Solid Dosage Form Forecasted Market Size by Application (2026-2031)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Semi-Solid Dosage Form Sales Breakdown by Application (2020-2025)
- 5.3.2 Europe Semi-Solid Dosage Form Sales Breakdown by Application (2020-2025)
- 5.3.3 Asia-Pacific Semi-Solid Dosage Form Sales Breakdown by Application (2020-2025)
- 5.3.4 South America Semi-Solid Dosage Form Sales Breakdown by Application (2020-2025)
- 5.3.5 Middle East and Africa Semi-Solid Dosage Form Sales Breakdown by Application (2020-2025)
- 6 Company Profiles
- 6.1 Aclaris Therapeutics, Inc.
- 6.1.1 Aclaris Therapeutics, Inc. Comapny Information
- 6.1.2 Aclaris Therapeutics, Inc. Business Overview
- 6.1.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.1.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
- 6.1.5 Aclaris Therapeutics, Inc. Recent Developments
- 6.2 Akorn Inc. (US)
- 6.2.1 Akorn Inc. (US) Comapny Information
- 6.2.2 Akorn Inc. (US) Business Overview
- 6.2.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.2.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
- 6.2.5 Akorn Inc. (US) Recent Developments
- 6.3 Allergan plc
- 6.3.1 Allergan plc Comapny Information
- 6.3.2 Allergan plc Business Overview
- 6.3.3 Allergan plc Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.3.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
- 6.3.5 Allergan plc Recent Developments
- 6.4 Almirall, S.A
- 6.4.1 Almirall, S.A Comapny Information
- 6.4.2 Almirall, S.A Business Overview
- 6.4.3 Almirall, S.A Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.4.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
- 6.4.5 Almirall, S.A Recent Developments
- 6.5 Bausch Health Companies
- 6.5.1 Bausch Health Companies Comapny Information
- 6.5.2 Bausch Health Companies Business Overview
- 6.5.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.5.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
- 6.5.5 Bausch Health Companies Recent Developments
- 6.6 Biofrontera, Inc.
- 6.6.1 Biofrontera, Inc. Comapny Information
- 6.6.2 Biofrontera, Inc. Business Overview
- 6.6.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.6.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
- 6.6.5 Biofrontera, Inc. Recent Developments
- 6.7 Cipla Ltd
- 6.7.1 Cipla Ltd Comapny Information
- 6.7.2 Cipla Ltd Business Overview
- 6.7.3 Cipla Ltd Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.7.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
- 6.7.5 Cipla Ltd Recent Developments
- 6.8 Crescita Therapeutics Inc.
- 6.8.1 Crescita Therapeutics Inc. Comapny Information
- 6.8.2 Crescita Therapeutics Inc. Business Overview
- 6.8.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.8.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
- 6.8.5 Crescita Therapeutics Inc. Recent Developments
- 6.9 Crown Laboratories Inc.
- 6.9.1 Crown Laboratories Inc. Comapny Information
- 6.9.2 Crown Laboratories Inc. Business Overview
- 6.9.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.9.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
- 6.9.5 Crown Laboratories Inc. Recent Developments
- 6.10 Encore Dermatology, Inc.
- 6.10.1 Encore Dermatology, Inc. Comapny Information
- 6.10.2 Encore Dermatology, Inc. Business Overview
- 6.10.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.10.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
- 6.10.5 Encore Dermatology, Inc. Recent Developments
- 6.11 Glenmark Pharmaceuticals
- 6.11.1 Glenmark Pharmaceuticals Comapny Information
- 6.11.2 Glenmark Pharmaceuticals Business Overview
- 6.11.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.11.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 6.11.5 Glenmark Pharmaceuticals Recent Developments
- 6.12 Hisamitsu Pharmaceutical
- 6.12.1 Hisamitsu Pharmaceutical Comapny Information
- 6.12.2 Hisamitsu Pharmaceutical Business Overview
- 6.12.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.12.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
- 6.12.5 Hisamitsu Pharmaceutical Recent Developments
- 6.13 Ingenus Pharmaceuticals
- 6.13.1 Ingenus Pharmaceuticals Comapny Information
- 6.13.2 Ingenus Pharmaceuticals Business Overview
- 6.13.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.13.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 6.13.5 Ingenus Pharmaceuticals Recent Developments
- 6.14 LEO Pharma
- 6.14.1 LEO Pharma Comapny Information
- 6.14.2 LEO Pharma Business Overview
- 6.14.3 LEO Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.14.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
- 6.14.5 LEO Pharma Recent Developments
- 6.15 Mylan N.V.
- 6.15.1 Mylan N.V. Comapny Information
- 6.15.2 Mylan N.V. Business Overview
- 6.15.3 Mylan N.V. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.15.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
- 6.15.5 Mylan N.V. Recent Developments
- 6.16 Novartis AG
- 6.16.1 Novartis AG Comapny Information
- 6.16.2 Novartis AG Business Overview
- 6.16.3 Novartis AG Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.16.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
- 6.16.5 Novartis AG Recent Developments
- 6.17 Perrigo Pharma
- 6.17.1 Perrigo Pharma Comapny Information
- 6.17.2 Perrigo Pharma Business Overview
- 6.17.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.17.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
- 6.17.5 Perrigo Pharma Recent Developments
- 6.18 Taro Pharmaceutical Industries Ltd.
- 6.18.1 Taro Pharmaceutical Industries Ltd. Comapny Information
- 6.18.2 Taro Pharmaceutical Industries Ltd. Business Overview
- 6.18.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.18.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
- 6.18.5 Taro Pharmaceutical Industries Ltd. Recent Developments
- 6.19 Teligent Pharma
- 6.19.1 Teligent Pharma Comapny Information
- 6.19.2 Teligent Pharma Business Overview
- 6.19.3 Teligent Pharma Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.19.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
- 6.19.5 Teligent Pharma Recent Developments
- 6.20 Bayer AG
- 6.20.1 Bayer AG Comapny Information
- 6.20.2 Bayer AG Business Overview
- 6.20.3 Bayer AG Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.20.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
- 6.20.5 Bayer AG Recent Developments
- 6.21 GlaxoSmithKline plc
- 6.21.1 GlaxoSmithKline plc Comapny Information
- 6.21.2 GlaxoSmithKline plc Business Overview
- 6.21.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.21.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
- 6.21.5 GlaxoSmithKline plc Recent Developments
- 6.22 Merck & Co
- 6.22.1 Merck & Co Comapny Information
- 6.22.2 Merck & Co Business Overview
- 6.22.3 Merck & Co Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.22.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
- 6.22.5 Merck & Co Recent Developments
- 6.23 Johnson & Johnson
- 6.23.1 Johnson & Johnson Comapny Information
- 6.23.2 Johnson & Johnson Business Overview
- 6.23.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.23.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
- 6.23.5 Johnson & Johnson Recent Developments
- 6.24 Nestlé SA
- 6.24.1 Nestlé SA Comapny Information
- 6.24.2 Nestlé SA Business Overview
- 6.24.3 Nestlé SA Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.24.4 Nestlé SA Semi-Solid Dosage Form Product Portfolio
- 6.24.5 Nestlé SA Recent Developments
- 6.25 Sun Pharmaceuticals
- 6.25.1 Sun Pharmaceuticals Comapny Information
- 6.25.2 Sun Pharmaceuticals Business Overview
- 6.25.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue and Gross Margin (2020-2025)
- 6.25.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
- 6.25.5 Sun Pharmaceuticals Recent Developments
- 7 North America by Country
- 7.1 North America Semi-Solid Dosage Form Sales by Country
- 7.1.1 North America Semi-Solid Dosage Form Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.1.2 North America Semi-Solid Dosage Form Sales by Country (2020-2025)
- 7.1.3 North America Semi-Solid Dosage Form Sales Forecast by Country (2026-2031)
- 7.2 North America Semi-Solid Dosage Form Market Size by Country
- 7.2.1 North America Semi-Solid Dosage Form Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2.2 North America Semi-Solid Dosage Form Market Size by Country (2020-2025)
- 7.2.3 North America Semi-Solid Dosage Form Market Size Forecast by Country (2026-2031)
- 8 Europe by Country
- 8.1 Europe Semi-Solid Dosage Form Sales by Country
- 8.1.1 Europe Semi-Solid Dosage Form Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.1.2 Europe Semi-Solid Dosage Form Sales by Country (2020-2025)
- 8.1.3 Europe Semi-Solid Dosage Form Sales Forecast by Country (2026-2031)
- 8.2 Europe Semi-Solid Dosage Form Market Size by Country
- 8.2.1 Europe Semi-Solid Dosage Form Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2.2 Europe Semi-Solid Dosage Form Market Size by Country (2020-2025)
- 8.2.3 Europe Semi-Solid Dosage Form Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific by Country
- 9.1 Asia-Pacific Semi-Solid Dosage Form Sales by Country
- 9.1.1 Asia-Pacific Semi-Solid Dosage Form Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.1.2 Asia-Pacific Semi-Solid Dosage Form Sales by Country (2020-2025)
- 9.1.3 Asia-Pacific Semi-Solid Dosage Form Sales Forecast by Country (2026-2031)
- 9.2 Asia-Pacific Semi-Solid Dosage Form Market Size by Country
- 9.2.1 Asia-Pacific Semi-Solid Dosage Form Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2.2 Asia-Pacific Semi-Solid Dosage Form Market Size by Country (2020-2025)
- 9.2.3 Asia-Pacific Semi-Solid Dosage Form Market Size Forecast by Country (2026-2031)
- 10 South America by Country
- 10.1 South America Semi-Solid Dosage Form Sales by Country
- 10.1.1 South America Semi-Solid Dosage Form Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.1.2 South America Semi-Solid Dosage Form Sales by Country (2020-2025)
- 10.1.3 South America Semi-Solid Dosage Form Sales Forecast by Country (2026-2031)
- 10.2 South America Semi-Solid Dosage Form Market Size by Country
- 10.2.1 South America Semi-Solid Dosage Form Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2.2 South America Semi-Solid Dosage Form Market Size by Country (2020-2025)
- 10.2.3 South America Semi-Solid Dosage Form Market Size Forecast by Country (2026-2031)
- 11 Middle East and Africa by Country
- 11.1 Middle East and Africa Semi-Solid Dosage Form Sales by Country
- 11.1.1 Middle East and Africa Semi-Solid Dosage Form Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.1.2 Middle East and Africa Semi-Solid Dosage Form Sales by Country (2020-2025)
- 11.1.3 Middle East and Africa Semi-Solid Dosage Form Sales Forecast by Country (2026-2031)
- 11.2 Middle East and Africa Semi-Solid Dosage Form Market Size by Country
- 11.2.1 Middle East and Africa Semi-Solid Dosage Form Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2.2 Middle East and Africa Semi-Solid Dosage Form Market Size by Country (2020-2025)
- 11.2.3 Middle East and Africa Semi-Solid Dosage Form Market Size Forecast by Country (2026-2031)
- 12 Value Chain and Sales Channels Analysis
- 12.1 Semi-Solid Dosage Form Value Chain Analysis
- 12.1.1 Semi-Solid Dosage Form Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Semi-Solid Dosage Form Production Mode & Process
- 12.2 Semi-Solid Dosage Form Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Semi-Solid Dosage Form Distributors
- 12.2.3 Semi-Solid Dosage Form Customers
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.